[go: up one dir, main page]

MXPA02008402A - Derivatives of quinoline as alpha-2 antagonists. - Google Patents

Derivatives of quinoline as alpha-2 antagonists.

Info

Publication number
MXPA02008402A
MXPA02008402A MXPA02008402A MXPA02008402A MXPA02008402A MX PA02008402 A MXPA02008402 A MX PA02008402A MX PA02008402 A MXPA02008402 A MX PA02008402A MX PA02008402 A MXPA02008402 A MX PA02008402A MX PA02008402 A MXPA02008402 A MX PA02008402A
Authority
MX
Mexico
Prior art keywords
quinoline
antagonists
alpha
derivatives
Prior art date
Application number
MXPA02008402A
Other languages
Spanish (es)
Inventor
Antti Haapalinna
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of MXPA02008402A publication Critical patent/MXPA02008402A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MXPA02008402A 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists. MXPA02008402A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (en) 2000-03-01 2000-03-01 Quinoline and naphthalene derivatives as alpha-2 antagonists
PCT/FI2001/000203 WO2001064645A2 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists

Publications (1)

Publication Number Publication Date
MXPA02008402A true MXPA02008402A (en) 2003-10-14

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008402A MXPA02008402A (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists.

Country Status (21)

Country Link
EP (1) EP1263733A2 (en)
JP (1) JP2003525274A (en)
KR (1) KR20020089372A (en)
CN (1) CN1468224A (en)
AR (1) AR034249A1 (en)
AU (1) AU2001239331A1 (en)
BR (1) BR0108816A (en)
CA (1) CA2400657A1 (en)
CZ (1) CZ20022880A3 (en)
EE (1) EE200200490A (en)
FI (1) FI20000480A0 (en)
HU (1) HUP0204458A3 (en)
IL (1) IL151093A0 (en)
MX (1) MXPA02008402A (en)
NO (1) NO20024159L (en)
PE (1) PE20011084A1 (en)
PL (1) PL357874A1 (en)
RU (1) RU2002125944A (en)
SK (1) SK12332002A3 (en)
WO (1) WO2001064645A2 (en)
ZA (1) ZA200206956B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
RU2361869C2 (en) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи New aryl - and heteroarylpiperazines
MXPA04009601A (en) 2002-04-03 2004-12-13 Orion Corp Polycyclic compounds as potent alpha2-adrenoceptor antagonists.
ATE521593T1 (en) * 2002-04-03 2011-09-15 Orion Corp USE OF AN ALFA2 ADRENORECEPTOR ANTAGONIST IN CNS-RELATED DISEASES
WO2003093240A1 (en) * 2002-04-30 2003-11-13 Yungjin Pharmaceutical Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
CN103110635A (en) 2005-07-04 2013-05-22 海波因特制药有限责任公司 Histamine H3 receptor antagonist
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
AU2006333522A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
RU2008150485A (en) * 2006-05-22 2010-06-27 Янссен Фармацевтика Н.В. (Be) SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
WO2007135111A1 (en) 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
ATE538116T1 (en) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-BENYODIOXOL-5-YL)-6-(4-CYCLOPROPYLPIPERAZINE-1-YL)-PYRIDAZINE, ITS SALTS AND SOLVATES AND THEIR USE AS A HISTAMINE H3 RECEPTOR ANTAGONIST
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (en) 2007-07-20 2014-10-21 Orion Corp 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
AR073628A1 (en) 2008-10-07 2010-11-17 Schering Corp BIARIL ANALOGS ESPIROAMINOOXAZOLINA AND ESPIROAMINODIAZOLINA MODULATORS OF ADRENERGIC RECEPTORS ALFA2C, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME IN ALLERGIC RHINITIS, CARDIAC DISORDERS AND OTHER DISEASES
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
MX2012006580A (en) * 2009-12-11 2012-09-28 Genecode As Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators.
CN103524413B (en) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 hydrogenated acridine derivative and application thereof
JOP20200052A1 (en) * 2013-12-19 2017-06-16 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
CA2944462A1 (en) 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (en) * 2017-07-01 2020-04-28 广东医科大学 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof
US20240398783A1 (en) * 2021-09-07 2024-12-05 Gismo Therapeutics, Inc. Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
CN1468224A (en) 2004-01-14
BR0108816A (en) 2002-12-10
EP1263733A2 (en) 2002-12-11
AU2001239331A1 (en) 2001-09-12
NO20024159D0 (en) 2002-08-30
KR20020089372A (en) 2002-11-29
WO2001064645A2 (en) 2001-09-07
SK12332002A3 (en) 2003-07-01
PE20011084A1 (en) 2001-10-25
CZ20022880A3 (en) 2003-06-18
CA2400657A1 (en) 2001-09-07
JP2003525274A (en) 2003-08-26
PL357874A1 (en) 2004-07-26
WO2001064645A3 (en) 2001-12-27
EE200200490A (en) 2003-12-15
RU2002125944A (en) 2004-02-27
AR034249A1 (en) 2004-02-18
FI20000480A0 (en) 2000-03-01
NO20024159L (en) 2002-08-30
IL151093A0 (en) 2003-04-10
HUP0204458A2 (en) 2003-04-28
HUP0204458A3 (en) 2004-07-28
ZA200206956B (en) 2003-12-01

Similar Documents

Publication Publication Date Title
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
EP1206262A4 (en) Npy antagonists: spiroisoquinolinone derivatives
NO20032449L (en) Urea-substituted imidazole quinoline ethers
ZA200108868B (en) Piperazine derivatives useful as CCR5 antagonists.
PL358216A1 (en) Carboxylic acid derivatives as ip antagonists
IL160750A0 (en) Quinoline derivatives as neuropeptide y antagonists
IL154053A0 (en) AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
AU9327501A (en) Quinolinone derivatives
AU2403802A (en) Benzimidazole derivatives
ZA200202775B (en) Quinazoline derivatives as VEGF inhibitors.
PL372295A1 (en) Quinoline derivatives as npy antagonists
AU2001263021A1 (en) Alkylamine derivatives of dihydropyridine npy antagonists
IL162377A0 (en) 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
AU2002224038A1 (en) Benzimidazole derivatives
IL153224A0 (en) 1,4-dihydropyridines as bradykinin antagonists
IL160060A0 (en) Piperidine derivatives useful as ccr5 antagonists
MXPA03006991A (en) Piperidinee derivatives as neurokinin 1 antagonists.
AU2002366320A1 (en) Lactams as tachykinin antagonists
AU2679401A (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
IL148623A0 (en) Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
IL152759A0 (en) Quinolonecarboxylic acid derivatives
AU2002226356A1 (en) Quinoline derivatives as nk-3 antagonists
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents